Key result
Elevated post-MI uPA, midkine, and GDF-15 link to adverse 12-month cardiac remodelling.
Why the study?
Cardiac remodelling after MI is associated with progressive heart failure, making early predictive biomarkers crucial.
Do elevated levels of specific circulating biomarkers (GDF-15, uPA, MK) predict the development of cardiac remodelling in patients after STEMI?
Case-Control (n=75)
No
Do elevated levels of specific circulating biomarkers (GDF-15, uPA, MK) predict the development of cardiac remodelling in patients after STEMI?
Answers are grounded in this paper and cite their sources.
Serum biomarkers GDF-15, uPA, and MK may serve as early predictors of adverse left ventricular remodelling after ST-elevation myocardial infarction.
Cardiac remodelling following myocardial infarction (MI) is a maladaptive change associated with progressive heart failure and compromises long-term clinical outcome. A substantial proportion of patients afflicted by MI still develop adverse outcomes associated with cardiac remodelling. Therefore, it is crucial to identify biomarkers for the early prediction of cardiac remodelling. An in-depth proteomics approach, including both semi-quantitative and quantitative antibody arrays, was used to identify circulating biomarkers that may be associated with detrimental cardiac remodelling. Furthermore, statistical correlation analysis was performed between the candidate biomarkers and clinical cardiac remodelling data to demonstrate their clinical utility. A systematic proteomics approach revealed that sclerostin (SOST), growth differentiation factor-15 (GDF-15), urokinase-type plasminogen activator (uPA), and midkine (MK) were increased, while monocyte chemotactic protein-3 (MCP-3) was uniquely decreased in MI patients who developed cardiac remodelling, compared to MI patients who did not develop cardiac remodelling and healthy humen. Moreover, correlation analyses between serum proteomes and cardiac remodelling echocardiographic parameters demonstrated a moderate positive association between left ventricular end-diastolic volume index (LVEDVi) and the three serum proteins, uPA, MK and GDF-15 (P < .05, respectively), and a moderate negative correlation between LV ejection fraction (LVEF) and these serum proteins (P < .05, respectively). Importantly, uPA and MK were firstly identified to be associated with the development of cardiac remodelling. The present study contributes to a better understanding of the various cytokines expressed during adverse cardiac remodelling. The identified biomarkers may facilitate early identification of patients at high risk of ischaemic heart failure pending further confirmation through larger clinical trials.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2020) conducted a case-control in Myocardial Infarction (n=75). Serum biomarkers (GDF-15, uPA, MK, SOST, MCP-3) vs. MI patients without cardiac remodelling and healthy controls was evaluated on Development of cardiac remodelling (>20% change in left ventricular end-diastolic volume index at 12 months) (p=<0.05). Elevated baseline serum levels of urokinase-type plasminogen activator (uPA), midkine (MK), and growth differentiation factor-15 (GDF-15) were significantly associated with the development of adverse cardiac remodelling at 12 months following myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: